Cytotheryx, a growing Rochester biotech firm working on treatments for liver disease, recently received $60 million in ...

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal co-dominant monogenic disorder characterized by lifelong low plasma levels of total ...

A study reveals advances in the understanding and treatment of liver fibrosis, a serious complication in the context of metabolic fatty liver disease, also known as MASLD (metabolic ...

In a breakthrough that brings bioengineered organs one step closer to reality, scientists have created lab-grown liver tissue capable of forming its own blood vessels. A team from Cincinnati ...

Scientists have discovered that blocking a key cellular enzyme thought to protect against fatty liver disease may instead ...

An international team of researchers bioengineering human liver tissues uncovered previously unknown networks of genetic-molecular crosstalk that control the organ's developmental processes – greatly ...

Pedestrians walk by the Pfizer corporate headquarters in New York City (2020). On Monday the company said it was discontinuing development of a weight-loss drug in pill form. File Photo by John ...

Pfizer announced on Monday that it is halting development of its oral weight-loss pill after one patient experienced liver issues. The company said it halted development of danuglipron, an oral drug ...